CNBX Pharmaceuticals Inc

CNBX Pharmaceuticals Inc a biopharmaceutical company engages in the discovery development and commercialization of cannabinoidbased treatments and therapies for cancer Its lead product candidate is RCC33 an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer The company is also developing various drug candidates including PLP33 for the treatment of lateral spreading or sessile and colorectal polyps during colonoscopy BRST33 to treat breast cancer MLN33 for the treatment of Melanoma and PRST33 to treat prostate cancer In addition it develops Cannabics SR a lipidbased capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexiacachexia syndrome and Cannabics CDx an exvivo drug sensitivity test The company was formerly known as Cannabics Pharmaceuticals Inc and changed its name to CNBX Pharmaceuticals Inc in March 2022 CNBX Pharmaceuticals Inc was incorporated in 2004 and is based in Bethesda Maryland CNBX Pharmaceuticals Inc is a subsidiary of Cannabics Inc